- Teams must be composed of at least one Principal Investigator from the KI (or MIT) and at least one Principal Investigator who is a member of DF/HCC. All applicants must be faculty members of their host institution and must meaningfully participate in the project as a real team. Preference will be given to teams that are employing unique and highly innovative approaches and new technologies.
- Teams may submit proposals focused on any aspect of translational cancer research. Preference will be given to work related to issues of high unmet medical need, for which advances in and/or technologies for early detection, more accurate diagnosis, monitoring, treatment, and prevention are required.